Alzheimer's disease in the retina: Imaging retinal Aβ plaques for early diagnosis and therapy assessment

Neurodegenerative Diseases

Volumn 10, Issue 1-4, 2012, Pages 285-293

  Koronyo, Yosef ^a   Salumbides, Brenda C ^a   Black, Keith L ^a   Koronyo Hamaoui, Maya ^a,b  

^a Department of Neurosurgery   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Amyloid plaques; Curcumin; Eye; Immunotherapy; Optical imaging; Prognosis; Retina; Vaccination

Indexed keywords

AMYLOID BETA PROTEIN; GLATIRAMER;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; HUMAN; IMMUNOTHERAPY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RETINA; RETINA DISEASE; VISUAL DISORDER;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CURCUMIN; DISEASE MODELS, ANIMAL; EARLY DIAGNOSIS; HUMANS; MICE; MICE, TRANSGENIC; NEUROIMAGING; PRESENILIN-1; RETINA; VISION DISORDERS;

EID: 84860217982     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000335154     Document Type: Article

References (107)

1. Chung JA, Cummings JL: Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. Neurol Clin 2000; 18: 829-846.
2. Weiner MF, Hynan LS, Bret ME, White C 3rd: Early behavioral symptoms and course of Alzheimer's disease. Acta Psychiatr Scand 2005; 111: 367-371.
3. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
4. Trojanowski JQ, Schmidt ML, Shin RW, Bramblett GT, Rao D, Lee VM: Altered tau and neurofilament proteins in neuro-degenerative diseases: diagnostic implications for Alzheimer's disease and Lewy body dementias. Brain Pathol 1993; 3: 45-54.
5. Selkoe DJ: Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008; 192: 106-113.
6. Lee VM: Regulation of tau phosphorylation in Alzheimer's disease. Ann NY Acad Sci 1996; 777: 107-113.
7. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH: Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 257-262.
8. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH: Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292.
9. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-279.
10. Reaume AG, Howland DS, Trusko SP, Savage MJ, Lang DM, Greenberg BD, Siman R, Scott RW: Enhanced amyloidogenic processing of the beta-amyloid precursor protein in genetargeted mice bearing the Swedish familial Alzheimer's disease mutations and a 'humanized' Abeta sequence. J Biol Chem 1996; 271: 23380-23388.
11. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA: Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-223.
12. Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H: Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci 2011; 34: 430-442.
13. Hampel H, Broich K, Hoessler Y, Pantel J: Biological markers for early detection and pharmacological treatment of Alzheimer's disease. Dialogues Clin Neurosci 2009; 11: 141-157.
14. Khan TK, Alkon DL: Early diagnostic accuracy and pathophysiologic relevance of an autopsy-confirmed Alzheimer's disease peripheral biomarker. Neurobiol Aging 2010; 31: 889-900.
15. Solomon PR, Murphy CA: Early diagnosis and treatment of Alzheimer's disease. Expert Rev Neurother 2008; 8: 769-780.
16. Farlow MR, Cummings JL: Effective pharmacologic management of Alzheimer's disease. Am J Med 2007; 120: 388-397.
17. Nordberg A: Amyloid imaging in early detection of Alzheimer's disease. Neurodegener Dis 2010; 7: 136-138.
18. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA: Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005; 25: 10598-10606.
19. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B: Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004; 55: 306-319.
20. Nakada T, Matsuzawa H, Igarashi H, Fujii Y, Kwee IL: In vivo visualization of senileplaque- like pathology in Alzheimer's disease patients by MR microscopy on a 7T system. J Neuroimaging 2008; 18: 125-129.
21. Wang Y, Klunk WE, Debnath ML, Huang GF, Holt DP, Shao L, Mathis CA: Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease. J Mol Neurosci 2004; 24: 55-62.
22. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L, Libri V, Leppert D, Beach TG: PIB is a non-specific imaging marker of amyloid- beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007; 130: 2607-2615.
23. Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, Ackermann U, Saunder T, Tochon-Danguy H, Jones G, Smith C, O'Keefe G, Masters CL, Rowe CC: Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med 2007; 48: 547-552.
24. Hintersteiner M, Enz A, Frey P, Jaton AL, Kinzy W, Kneuer R, Neumann U, Rudin M, Staufenbiel M, Stoeckli M, Wiederhold KH, Gremlich HU: In vivo detection of amyloidbeta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol 2005; 23: 577-583.
25. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, Schwartz M, Farkas DL: Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 2011; 54:S204-S217.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944.
27. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269.
28. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Langstrom B, Nordberg A: Two-year follow- up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129: 2856-2866.
29. Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, Blankenstein MA: Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 2010; 56: 248-253.
30. Bouwman FH, Schoonenboom NS, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, Scheltens P, van der Flier WM: CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol Aging 2009; 30: 1895-1901.
31. Schoonenboom NS, van der Flier WM, Blankenstein MA, Bouwman FH, Van Kamp GJ, Barkhof F, Scheltens P: CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging 2008; 29: 669-675.
32. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM: Decreased beta-amyloid1- 42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289: 2094-2103.
33. Lister-James J, Pontecorvo MJ, Clark C, Joshi AD, Mintun MA, Zhang W, Lim N, Zhuang Z, Golding G, Choi SR, Benedum TE, Kennedy P, Hefti F, Carpenter AP, Kung HF, Skovronsky DM: Florbetapir f-18: a histopathologically validated beta-amyloid positron emission tomography imaging agent. Semin Nucl Med 2011; 41: 300-304.
34. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, Pirraglia E, De Santi S, Reisberg B, Wisniewski T, de Leon MJ: FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009; 36: 811-822.
35. Stefanova E, Wall A, Almkvist O, Nilsson A, Forsberg A, Langstrom B, Nordberg A: Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J Neural Transm 2006; 113: 205-218.
36. Dierks T, Jelic V, Pascual-Marqui RD, Wahlund L, Julin P, Linden DE, Maurer K, Winblad B, Nordberg A: Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzheimer's disease. Clin Neurophysiol 2000; 111: 1817-1824.
37. Luckhaus C, Janner M, Cohnen M, Fluss MO, Teipel SJ, Grothe M, Hampel H, Kornhuber J, Ruther E, Peters O, Supprian T, Gaebel W, Modder U, Wittsack HJ: A novel MRI-biomarker candidate for Alzheimer's disease composed of regional brain volume and perfusion variables. Eur J Neurol 2010; 17: 1437-1444.
38. Maheswaran S, Barjat H, Rueckert D, Bate ST, Howlett DR, Tilling L, Smart SC, Pohlmann A, Richardson JC, Hartkens T, Hill DL, Upton N, Hajnal JV, James MF: Longitudinal regional brain volume changes quantified in normal aging and Alzheimer's APP ! PS1 mice using MRI. Brain Res 2009; 1270: 19-32.
39. Stefani A, Sancesario G, Pierantozzi M, Leone G, Galati S, Hainsworth AH, Diomedi M: CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia. J Neurol Sci 2009; 283: 109-115.
40. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR: PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006; 355: 2652-2663.
41. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM: Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305: 275-283.
42. Vallabhajosula S: Positron emission tomography radiopharmaceuticals for imaging brain beta-amyloid. Semin Nucl Med 2011; 41: 283-299.
43. Ono M, Saji H: SPECT imaging agents for detecting cerebral beta-amyloid plaques. Int J Mol Imaging 2011; 2011: 543267.
44. Dhenain M, Delatour B, Walczak C, Volk A: Passive staining: a novel ex vivo MRI protocol to detect amyloid deposits in mouse models of Alzheimer's disease. Magn Reson Med 2006; 55: 687-693.
45. Meadowcroft MD, Connor JR, Smith MB, Yang QX: MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice. J Magn Reson Imaging 2009; 29: 997-1007.
46. Teipel SJ, Kaza E, Hadlich S, Bauer A, Bruning T, Plath AS, Krohn M, Scheffler K, Wal ker LC, Lotze M, Pahnke J: Automated de tection of amyloid-beta-related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using highfield MRI. J Alzheimers Dis 2011; 23: 221-237.
47. Nobili F, De Carli F, Frisoni GB, Portet F, Verhey F, Rodriguez G, Caroli A, Touchon J, Morbelli S, Guerra UP, Dessi B, Brugnolo A, Visser PJ: SPECT predictors of cognitive decline and Alzheimer's disease in mild cognitive impairment. J Alzheimers Dis 2009; 17: 761-772.
48. Ran C, Xu X, Raymond SB, Ferrara BJ, Neal K, Bacskai BJ, Medarova Z, Moore A: Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits. J Am Chem Soc 2009; 131: 15257-15261.
49. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT: Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008; 451: 720-724.
50. Dong J, Revilla-Sanchez R, Moss S, Haydon PG: Multiphoton in vivo imaging of amyloid in animal models of Alzheimer's disease. Neuropharmacology 2010; 59: 268-275.
51. Frost S, Martins RN, Kanagasingam Y: Ocular biomarkers for early detection of Alzheimer's disease. J Alzheimers Dis 2010; 22: 1-16.
52. Normando EM, Coxon KM, Guo L, Cordeiro MF: Focus on: amyloid beta. Exp Eye Res 2009; 89: 446-447.
53. Maude RJ, Dondorp AM, Abu Sayeed A, Day NP, White NJ, Beare NA: The eye in cerebral malaria: what can it teach us? Trans R Soc Trop Med Hyg 2009; 103: 661-664.
54. Byerly MS, Blackshaw S: Vertebrate retina and hypothalamus development. Wiley Interdiscip Rev Syst Biol Med 2009; 1: 380-389.
55. Morin PJ, Abraham CR, Amaratunga A, Johnson RJ, Huber G, Sandell JH, Fine RE: Amyloid precursor protein is synthesized by retinal ganglion cells, rapidly transported to the optic nerve plasma membrane and nerve terminals, and metabolized. J Neurochem 1993; 61: 464-473.
56. Chiu K, Chan TF, Wu A, Leung IY, So KF, Chang RC: Neurodegeneration of the retina in mouse models of Alzheimer's disease: what can we learn from the retina? Age (Dordr), E-pub ahead of print.
57. Blanks JC, Schmidt SY, Torigoe Y, Porrello KV, Hinton DR, Blanks RH: Retinal pathology in Alzheimer's disease. 2. Regional neuron loss and glial changes in GCL. Neurobiol Aging 1996; 17: 385-395.
58. Blanks JC, Torigoe Y, Hinton DR, Blanks RH: Retinal pathology in Alzheimer's disease. 1. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging 1996; 17: 377-384.
59. Hinton DR, Sadun AA, Blanks JC, Miller CA: Optic-nerve degeneration in Alzheimer's disease. N Engl J Med 1986; 315: 485-487.
60. Parisi V: Correlation between morphological and functional retinal impairment in patients affected by ocular hypertension, glaucoma, demyelinating optic neuritis and Alzheimer's disease. Semin Ophthalmol 2003; 18: 50-57.
61. Parisi V, Restuccia R, Fattapposta F, Mina C, Bucci MG, Pierelli F: Morphological and functional retinal impairment in Alzheimer's disease patients. Clin Neurophysiol 2001; 112: 1860-1867.
62. Greeve I, Kretzschmar D, Tschape JA, Beyn A, Brellinger C, Schweizer M, Nitsch RM, Reifegerste R: Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic drosophila. J Neurosci 2004; 24: 3899-3906.
63. Ning A, Cui J, To E, Ashe KH, Matsubara J: Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci 2008; 49: 5136-5143.
64. Perez SE, Lumayag S, Kovacs B, Mufson EJ, Xu S: Beta-amyloid deposition and functional impairment in the retina of the APPswe/ ps1DeltaE9 transgenic mouse model of Alzheimer's disease. Invest Ophthalmol Vis Sci 2009; 50: 793-800.
65. Liu B, Rasool S, Yang Z, Glabe CG, Schreiber SS, Ge J, Tan Z: Amyloid-peptide vaccinations reduce beta-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice. Am J Pathol 2009; 175: 2099-2110.
66. Dutescu RM, Li QX, Crowston J, Masters CL, Baird PN, Culvenor JG: Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1213-1221.
67. Loffler KU, Edward DP, Tso MO: Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina. Invest Ophthalmol Vis Sci 1995; 36: 24-31.
68. Seth A, Cui J, To E, Kwee M, Matsubara J: Complement-associated deposits in the human retina. Invest Ophthalmol Vis Sci 2008; 49: 743-750.
69. Katz B, Rimmer S: Ophthalmologic manifestations of Alzheimer's disease. Surv Ophthalmol 1989; 34: 31-43.
70. Katz B, Rimmer S, Iragui V, Katzman R: Abnormal pattern electroretinogram in Alzheimer's disease: evidence for retinal ganglion cell degeneration? Ann Neurol 1989; 26: 221-225.
71. Sadun AA, Borchert M, DeVita E, Hinton DR, Bassi CJ: Assessment of visual impairment in patients with Alzheimer's disease. Am J Ophthalmol 1987; 104: 113-120.
72. Trick GL, Barris MC, Bickler-Bluth M: Abnormal pattern electroretinograms in patients with senile dementia of the Alzheimer type. Ann Neurol 1989; 26: 226-231.
73. Valenti DA: Alzheimer's disease: visual system review. Optometry 2010; 81: 12-21.
74. Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL: Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci 2007; 48: 2285-2289.
75. Curcio CA, Drucker DN: Retinal ganglion cells in Alzheimer's disease and aging. Ann Neurol 1993; 33: 248-257.
76. Guo L, Duggan J, Cordeiro MF: Alzheimer's disease and retinal neurodegeneration. Curr Alzheimer Res 2010; 7: 3-14.
77. Jindahra P, Hedges TR, Mendoza-Santiesteban CE, Plant GT: Optical coherence tomography of the retina: applications in neurology. Curr Opin Neurol 2010; 23: 16-23.
78. McGeer PL, McGeer EG: Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol 2002; 8: 529-538.
79. Wyss-Coray T: Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006; 12: 1005-1015.
80. Armstrong RA: Beta-amyloid plaques: stages in life history or independent origin? Dement Geriatr Cogn Disord 1998; 9: 227-238.
81. Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, Van Gelder P, Hartmann D, D'Hooge R, De Strooper B, Schymkowitz J, Rousseau F: Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J 2008; 27: 224-233.
82. Danesh-Meyer HV, Birch H, Ku JY, Carroll S, Gamble G: Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology 2006; 67: 1852-1854.
83. Kesler A, Vakhapova V, Korczyn AD, Naftaliev E, Neudorfer M: Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clin Neurol Neurosurg 2011; 113: 523-526.
84. Lu Y, Li Z, Zhang X, Ming B, Jia J, Wang R, Ma D: Retinal nerve fiber layer structure abnormalities in early Alzheimer's disease: evidence in optical coherence tomography. Neurosci Lett 2010; 480: 69-72.
85. Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J: Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2007; 420: 97-99.
86. van Velthoven ME, Faber DJ, Verbraak FD, van Leeuwen TG, de Smet MD: Recent developments in optical coherence tomography for imaging the retina. Prog Retin Eye Res 2007; 26: 57-77.
87. Krasodomska K, Lubinski W, Potemkowski A, Honczarenko K: Pattern electroretinogram (PERG) and pattern visual evoked potential (PVEP) in the early stages of Alzheimer's disease. Doc Ophthalmol 2010; 121: 111-121.
88. Cordeiro MF, Guo L, Coxon KM, Duggan J, Nizari S, Normando EM, Sensi SL, Sillito AM, Fitzke FW, Salt TE, Moss SE: Imaging multiple phases of neurodegeneration: a novel approach to assessing cell death in vivo. Cell Death Dis 2010; 1: 1-11.
89. Guo L, Salt TE, Maass A, Luong V, Moss SE, Fitzke FW, Cordeiro MF: Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo. Invest Ophthalmol Vis Sci 2006; 47: 626-633.
90. Guo L, Moss SE, Alexander RA, Ali RR, Fitzke FW, Cordeiro MF: Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest Ophthalmol Vis Sci 2005; 46: 175-182.
91. Reinke AA, Gestwicki JE: Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des 2007; 70: 206-215.
92. Yanagisawa D, Shirai N, Amatsubo T, Taguchi H, Hirao K, Urushitani M, Morikawa S, Inubushi T, Kato M, Kato F, Morino K, Kimura H, Nakano I, Yoshida C, Okada T, Sano M, Wada Y, Wada KN, Yamamoto A, Tooyama I: Relationship between the tautomeric structures of curcumin derivatives and their Abeta-binding activities in the context of therapies for Alzheimer's disease. Biomaterials 2010; 31: 4179-4185.
93. Ryu EK, Choe YS, Lee KH, Choi Y, Kim BT: Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem 2006; 49: 6111-6119.
94. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ: Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 2007; 102: 1095-1104.
95. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM: Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005; 280: 5892-5901.
96. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-4499.
97. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA: Curcumin structurefunction, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 2008; 326: 196-208.
98. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL: A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2005; 2: 131-136.
99. Aggarwal BB, Kumar A, Bharti AC: Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363-398.
100. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB: Bioavailability of curcumin: problems and promises. Mol Pharm 2007; 4: 807-818.
101. Butovsky O, Koronyo-Hamaoui M, Kunis G, Ophir E, Landa G, Cohen H, Schwartz M: Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci USA 2006; 103: 11784-11789.
102. Butovsky O, Kunis G, Koronyo-Hamaoui M, Schwartz M: Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. Eur J Neurosci 2007; 26: 413-416.
103. Koronyo-Hamaoui M, Ko MK, Koronyo Y, Azoulay D, Seksenyan A, Kunis G, Pham M, Bakhsheshian J, Rogeri P, Black KL, Farkas DL, Schwartz M: Attenuation of ADlike neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J Neurochem 2009; 111: 1409-1424.
104. Bakalash S, Pham M, Koronyo Y, Salumbides BC, Kramerov A, Seidenberg H, Berel D, Black KL, Koronyo-Hamaoui M: Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease. Invest Ophthalmol Vis Sci 2011; 52: 9033-9046.
105. Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A, Ferrari G, Russo-Marie F, Sillito AM, Cheetham ME, Moss SE, Fitzke FW, Cordeiro MF: Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA 2007; 104: 13444-13449.
106. Ding JD, Lin J, Mace BE, Herrmann R, Sullivan P, Bowes Rickman C: Targeting agerelated macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res 2008; 48: 339-345.
107. Ding JD, Johnson LV, Herrmann R, Farsiu S, Smith SG, Groelle M, Mace BE, Sullivan P, Jamison JA, Kelly U, Harrabi O, Bollini SS, Dilley J, Kobayashi D, Kuang B, Li W, Pons J, Lin JC, Bowes Rickman C: Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci USA 2011; 108:E279-E287.